Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Update

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) was the recipient of a large drop in short interest during the month of August. As of August 31st, there was short interest totaling 25,053 shares, a drop of 65.5% from the August 15th total of 72,693 shares. Based on an average trading volume of 17,420 shares, the short-interest ratio is presently 1.4 days. Currently, 0.0% of the company’s shares are short sold.

Pharming Group Trading Up 3.7%

Shares of Pharming Group stock traded up $0.40 during trading on Friday, hitting $11.21. The stock had a trading volume of 39,065 shares, compared to its average volume of 15,702. Pharming Group has a 12 month low of $9.62 and a 12 month high of $21.34. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.01 and a quick ratio of 2.31. The firm’s fifty day simple moving average is $12.07 and its 200-day simple moving average is $13.86. The stock has a market cap of $793.44 million, a PE ratio of 93.42 and a beta of 0.01.

Pharming Group (NASDAQ:PHAR) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.06 by ($0.04). Pharming Group had a net margin of 2.51% and a return on equity of 3.40%. As a group, sell-side analysts expect that Pharming Group will post 0.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Pharming Group

A number of large investors have recently bought and sold shares of PHAR. EverSource Wealth Advisors LLC bought a new position in Pharming Group in the 2nd quarter valued at $32,000. SmartHarvest Portfolios LLC bought a new stake in shares of Pharming Group during the fourth quarter worth $224,000. Millennium Management LLC purchased a new stake in shares of Pharming Group during the fourth quarter valued at $360,000. Finally, NewEdge Advisors LLC boosted its stake in shares of Pharming Group by 11,310.3% during the fourth quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock valued at $510,000 after purchasing an additional 28,615 shares during the period. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Weiss Ratings reissued a “sell (d)” rating on shares of Pharming Group in a research note on Friday, August 7th. Zacks Research lowered Pharming Group from a “hold” rating to a “strong sell” rating in a research note on Friday, July 31st. Canaccord Genuity Group lifted their target price on Pharming Group from $37.00 to $38.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Finally, Oppenheimer reissued an “outperform” rating on shares of Pharming Group in a research report on Thursday, July 30th. Three analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $38.67.

Pharming Group Company Profile

Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands, focused on developing and commercializing treatments for rare diseases. The company uses its expertise in protein replacement therapies and other biotechnology platforms to address conditions with limited treatment options.

Pharming’s principal product is Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause severe swelling.